Brolucizumab is a Monoclonal Antibody owned by Athenex, and is involved in 31 clinical trials, of which 12 were completed, 15 are ongoing, and 4 are planned.
Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF110, VEGF121, and VEGF165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability
Brolucizumab (DLX-1008) is a VEGF-A inhibitor. It binds to VEGF-A and prevents the interaction of VEGF-A to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF-A with its receptors leads to endothelial cell proliferation and new blood vessel formation of angiogenesis. Blocking VEGF-A reduces the growth of new blood vessels.
The revenue for Brolucizumab is expected to reach a total of $6.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Brolucizumab NPV Report.
Brolucizumab-dbll (Beovu, Vsiqq, Vizcu, Pagenax) is a recombinant human vascular endothelial growth factor. It is formulated as solution for intravitreal route of administration. Beovu is indicated for the treatment of neovascular (Wet) age-related macular degeneration. Beovu is indicated for the treatment of diabetic macular edema.
Brolucizumab (DLX-1008) is under development for proliferative diabetic retinopathy. It is administered topically and intravitreally. The therapeutic candidate targets VEGF-A and is developed based on the Pentra technology platform which utilizes Pentra antibody fragments. It was also under development for the treatment of keloids, rosacea, Kaposi's sarcoma, diabetic macular edema and glioblastoma.
It was under development for the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion, macular edema secondary to central retinal vein occlusion.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Brolucizumab
|Highest Development Stage|